IDH1 and acute myeloid leukemia: As a single agent, in a phase 2 clinical trial, olutasidenib induced an ORR of 46% in patients with IDH1-mutated R/R AML, but the presence of co-mutations (NPM1, DNMT3A, ASXL1, and receptor tyrosine kinase (RTK) genes) was correlated with decreased ORR and CR [114].